granupas (previously para-aminosalicylic acid lucane)
eurocept international b. v. - para-amminosalicilico - tubercolosi - antimicobatterici - granupas è indicato per l'uso come parte di un regime di combinazione appropriata per la tubercolosi multi-farmaco resistente in pazienti adulti e pediatrici da 28 giorni di età e più anziani quando un regime terapeutico efficace altrimenti non può essere composta per motivi di resistenza o tollerabilità (vedere paragrafo 4. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
pramipexol-mepha er 0.375 mg depotabs
mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 0.375 mg corresp. pramipexolum 0.26 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika
pramipexol-mepha er 0.75 mg depotabs
mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 0.750 mg corresp. pramipexolum 0.52 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika
pramipexol-mepha er 1.5 mg depotabs
mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 1.500 mg corresp. pramipexolum 1.05 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika
pramipexol-mepha er 3 mg depotabs
mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 3.000 mg corresp. pramipexolum 2.1 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika
pramipexol-mepha er 4.5 mg depotabs
mepha pharma ag - pramipexolum - depotabs - pramipexoli dihydrochloridum monohydricum 4.500 mg corresp. pramipexolum 3.15 mg, hypromellosum, calcii hydrogenophosphas, magnesii stearas, silica colloidalis anhydrica pro compresso. - morbo di parkinson - synthetika
draximage xenon xe 133 gas zur inhalation
heider ag - xenonum(133-xe) - gas zur inhalation - xenonum(133-xe) 74 -740 mbq, gasum inhalationis, pro vitro. - lungenszintigraphie - radiopharmazeutika
clordiazepossido cloridrato
montefarmaco otc s.p.a. - clordiazepossido - clordiazepossido
clordiazepossido cloridrato
laboratorio farmacologico milanese s.r.l. - clordiazepossido - clordiazepossido